{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:14:39Z","timestamp":1792365279269,"version":"4.4.0"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T00:00:00Z","timestamp":1428278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005616","name":"Allergan, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005616","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To identify the self\u2010reported treatment goals of patients with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO), determine whether patients achieved their goals following onabotulinumtoxinA treatment, and assess impact of neurogenic disease (multiple sclerosis or spinal cord injury) and\/or clean intermittent catheterization (CIC) on goal achievement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from two Phase III studies of onabotulinumtoxinA 200U (n\u2009=\u2009227) or placebo (n\u2009=\u2009241) in NDO patients (\u226514 UI episodes\/week; inadequately managed by anticholinergics) were pooled for analysis. At baseline, patients listed their top two qualitative treatment goals, which were distributed into eight subcategories. Six weeks post\u2010treatment, patients rated whether they achieved their goals (5\u2010point Likert scale). The frequency distribution of goals, the proportion of patients who achieved their goals, and goal achievement by etiology and use\/non\u2010use of CIC were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the most common goals were \u201cbe dry\u201d (37.9%), \u201creduce other urinary symptoms\u201d (26.4%), and \u201cimprove quality of life\/sleep\/emotions\u201d (21.4%). Significantly higher proportions of onabotulinumtoxinA\u2010treated patients achieved their overall goals versus placebo (62.0% vs. 17.2%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009 0.001). OnabotulinumtoxinA treatment resulted in higher goal achievement in all goal categories, regardless of etiology. CIC use did not negatively impact patients\u2019 overall goal achievement; significantly higher proportions of onabotulinumtoxinA\u2010treated patients versus placebo achieved their goals regardless of baseline catheterization use or de novo CIC during the first 6 weeks of the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The majority of patients with UI due to NDO achieved their self\u2010determined treatment goals following onabotulinumtoxinA 200U therapy, regardless of etiology or CIC use.\n                      <jats:italic>Neurourol. Urodynam. 35:595\u2013600, 2016<\/jats:italic>\n                      . \u00a9 2015 The Authors.\n                      <jats:italic>Neurourology and Urodynamics<\/jats:italic>\n                      , published by Wiley Periodicals, Inc.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.22757","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T11:09:45Z","timestamp":1428318585000},"page":"595-600","source":"Crossref","is-referenced-by-count":9,"title":["Patient\u2010reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity"],"prefix":"10.1002","volume":"35","author":[{"given":"Emmanuel","family":"Chartier\u2010Kastler","sequence":"first","affiliation":[{"name":"Department of Urology Piti\u00e9\u2010Salp\u00e9tri\u00e8re Academic Hospital University Paris 6 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rovner","sequence":"additional","affiliation":[{"name":"Department of Urology Medical University of South Carolina Charleston South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[{"name":"Global Health Outcomes Strategy and Research Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Khalaf","sequence":"additional","affiliation":[{"name":"Global Health Outcomes Strategy and Research Allergan, Inc. Irvine California"},{"name":"Department of Pharmaceutical Sciences University of Arizona Phoenix Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhong","family":"Ni","sequence":"additional","affiliation":[{"name":"Global Health Outcomes Strategy and Research Allergan, Inc. Irvine California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chancellor","sequence":"additional","affiliation":[{"name":"Neurourology Department Beaumont Hospital Royal Oak Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9590-z"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200006000-00005"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-200112000-00008"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-9993(98)90240-4"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22376"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0054-z"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a2ca4d"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22293"},{"key":"e_1_2_8_12_1","unstructured":"BOTOX. Irvine CA: Allergan Inc;2014."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S65603"},{"key":"e_1_2_8_14_1","unstructured":"Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox\/Botox Cosmetic) AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc).www.fda.gov2013[cited 2014 November 26]; Available from:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174949.htm."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02951.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-011-1360-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01652.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09508.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-007-0390-0"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2013-040"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.12.002"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22670"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181a1f5ea"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-011-1655-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20616"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.028"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22757","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.22757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22757","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.22757","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.22757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:00:54Z","timestamp":1696334454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.22757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,6]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1002\/nau.22757"],"URL":"https:\/\/doi.org\/10.1002\/nau.22757","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,6]]}}}